{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T11:06:14Z","timestamp":1770980774472,"version":"3.50.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"suppl_5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,11,15]]},"DOI":"10.1093\/cid\/civ500","type":"journal-article","created":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T00:33:10Z","timestamp":1447115590000},"page":"S483-S488","source":"Crossref","is-referenced-by-count":10,"title":["Challenges and Opportunities While Developing a Group A Meningococcal Conjugate Vaccine Within a Product Development Partnership: A Manufacturer's Perspective From the Serum Institute of India"],"prefix":"10.1093","volume":"61","author":[{"given":"Prasad S.","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muriel","family":"Socquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh S.","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhash V.","family":"Kapre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. Marc","family":"LaForce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrus S.","family":"Poonawalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,11,9]]},"reference":[{"key":"key\n\t\t\t\t20171014014050_CIV500C1","first-page":"33","article-title":"The vaccine industry","volume-title":"Vaccines","year":"2012","edition":"6th ed"},{"key":"key\n\t\t\t\t20171014014050_CIV500C2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1365-3156.2006.01639.x","article-title":"100 years of meningitis in West Africa: has anything changed?","volume":"11","year":"2006","journal-title":"Trop Med Int Health"},{"key":"key\n\t\t\t\t20171014014050_CIV500C3","first-page":"399","article-title":"Meningococcal vaccines","volume-title":"Vaccines","year":"2008","edition":"5th ed"},{"key":"key\n\t\t\t\t20171014014050_CIV500C4","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/S0140-6736(03)13494-0","article-title":"Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries","volume":"361","year":"2003","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171014014050_CIV500C5","article-title":"Introduction of a group A meningococcal conjugate vaccine in sub-Saharan Africa: cost\/savings analysis, Meningitis Vaccine Project","year":"2008"},{"issue":"suppl 1","key":"key\n\t\t\t\t20171014014050_CIV500C6","first-page":"A97","article-title":"The Meningitis Vaccine Project","volume":"3","year":"2007","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014014050_CIV500C7","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1377\/hlthaff.2011.0328","article-title":"Eliminating epidemic group A meningococcal meningitis in Africa through a new vaccine","volume":"30","year":"2011","journal-title":"Health Affairs (Millwood)"},{"key":"key\n\t\t\t\t20171014014050_CIV500C8","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1003812","article-title":"Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014014050_CIV500C9","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/cid\/cis892","article-title":"Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity","volume":"56","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014014050_CIV500C10","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1473-3099(12)70168-8","article-title":"Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data","volume":"12","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"suppl 1","key":"key\n\t\t\t\t20171014014050_CIV500C11","first-page":"S1","article-title":"Public-private partnerships: an overview","volume":"99","year":"2005","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key\n\t\t\t\t20171014014050_CIV500C12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1478-4505-9-33","article-title":"Product development partnerships: case studies of a new mechanism for health technology innovation","volume":"9","year":"2011","journal-title":"Health Res Policy Syst"},{"key":"key\n\t\t\t\t20171014014050_CIV500C13","article-title":"Milestones","author":"Serum Institute of India, Ltd"},{"key":"key\n\t\t\t\t20171014014050_CIV500C14","first-page":"190","article-title":"Public-private partnership in global health: addressing issues of public accountability, risk management and governance","volume":"36","year":"2012","journal-title":"Public Adm Q"},{"key":"key\n\t\t\t\t20171014014050_CIV500C15","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.vaccine.2008.11.065","article-title":"Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa","volume":"27","year":"2009","journal-title":"Vaccine"},{"issue":"suppl 1","key":"key\n\t\t\t\t20171014014050_CIV500C16","first-page":"A101","article-title":"Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults","volume":"25","year":"2007","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014014050_CIV500C17","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.1016\/j.vaccine.2012.08.004","article-title":"Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2\u201310 years: a phase II\/III double-blind randomized controlled trial","volume":"30","year":"2012","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014014050_CIV500C18","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1128\/CVI.00812-13","article-title":"Development and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlers","volume":"21","year":"2014","journal-title":"Clin Vac Immunol"},{"issue":"suppl 2","key":"key\n\t\t\t\t20171014014050_CIV500C19","first-page":"B40","article-title":"Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience","volume":"30","year":"2012","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014014050_CIV500C20","doi-asserted-by":"crossref","first-page":"12307","DOI":"10.1073\/pnas.1400473111","article-title":"Vaccines against poverty","volume":"111","year":"2014","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/61\/suppl_5\/S483\/20913984\/civ500.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T05:40:55Z","timestamp":1507959655000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/61\/suppl_5\/S483\/417594\/Challenges-and-Opportunities-While-Developing-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,9]]},"references-count":20,"journal-issue":{"issue":"suppl_5","published-online":{"date-parts":[[2015,11,9]]},"published-print":{"date-parts":[[2015,11,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/civ500","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,11,15]]},"published":{"date-parts":[[2015,11,9]]}}}